Table 5.
Multivariate Cox analysis of the overall survival (OS) and progression-free survival (PFS) among 327 patients having either cytogenetic abnormalities (CAs) or histologic BM involvement (BMIhisto+) and among R-CHOP treated patients (n = 200)*
| |
|
OS |
PFS |
||||
|---|---|---|---|---|---|---|---|
| Risk factors | No. of patients (%) | HR | 95% CI | P | HR | 95% CI | P |
|
Total patients with CAs and/or BMIhisto+ (n = 327) |
|
|
|
|
|
|
|
| Presence of ≥ 2 cytogenetic abnormalities as a risk factor |
|
|
|
|
|
|
|
| IPI risk group, high vs. low |
123 (37.6) |
6.46 |
1.56-26.72 |
0.010 |
7.15 |
1.73-29.46 |
0.007 |
| R-CHOP treatment, R-CHOP vs. others |
200 (61.2) |
0.26 |
0.18-0.35 |
<0.001 |
0.38 |
0.28-0.51 |
<0.001 |
| ≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality |
138 (42.2) |
2.49 |
1.75-3.54 |
<0.001 |
2.12 |
1.53-2.93 |
<0.001 |
| Presence of specific cytogenetic abnormalities as risk factors |
|
|
|
|
|
|
|
| IPI risk group, high vs. low |
123 (37.6) |
8.34 |
2.04-24.09 |
0.003 |
8.43 |
2.06-34.44 |
0.003 |
| R-CHOP treatment, R-CHOP vs. others |
200 (61.2) |
0.24 |
0.17-0.34 |
<0.001 |
0.32 |
0.24-0.44 |
<0.001 |
| 19p13 abnormality present vs. absent |
24 (7.3) |
2.67 |
1.50-4.76 |
0.001 |
3.02 |
1.85-4.93 |
<0.001 |
| 7q22 abnormality present vs. absent |
11 (3.4) |
3.03 |
1.51.-6.06 |
0.002 |
NS |
NS |
NS |
| 12q22-q24 abnormality present vs. absent |
12 (3.7) |
2.68 |
1.37.-5.26 |
0.004 |
NS |
NS |
NS |
| 18q21 abnormality present vs. absent |
21 (6.4) |
2.11 |
1.22.-3.64 |
0.007 |
NS |
NS |
NS |
| 16q22-q24 abnormality present vs. absent |
14 (4.3) |
2.27 |
1.23-4.18 |
0.009 |
NS |
NS |
NS |
| 11q23-q25 abnormality present vs. absent |
19 (5.8) |
1.81 |
1.03-3.15 |
0.038 |
NS |
NS |
NS |
| 8q24 abnormality present vs. absent |
19 (5.8) |
NS |
NS |
NS |
2.61 |
1.54-4.43 |
<0.001 |
|
R-CHOP treated patients with CAs and/or BMIhisto+ (n = 200) |
|
|
|
|
|
|
|
| Presence of ≥ 2 cytogenetic abnormalities as a risk factor |
|
|
|
|
|
|
|
| IPI risk group, high vs. low |
67 (33.5) |
5.29 |
1.23-22.86 |
0.026 |
5.55 |
1.32-23.37 |
0.020 |
| Male vs. female |
112 (56.0) |
1.71 |
1.01-2.91 |
0.046 |
NS |
NS |
NS |
| ≥ 2 cytogenetic abnormalities vs. 0 or 1 abnormality |
78 (39.0) |
2.01 |
1.17-3.45 |
0.012 |
2.15 |
1.38-3.38 |
0.001 |
| Presence of specific cytogenetic abnormalities as risk factors |
|
|
|
|
|
|
|
| IPI risk group, high vs. low |
67 (33.5) |
5.92 |
1.40-25.04 |
0.016 |
7.61 |
1.82-31.92 |
0.006 |
| Male vs. female |
112 (56.0) |
2.00 |
1.15-3.47 |
0.014 |
1.71 |
1.09-2.69 |
0.021 |
| 19q13 abnormality present vs. absent |
13 (6.5) |
3.36 |
1.50-7.54 |
0.003 |
NS |
NS |
NS |
| 12q22-q24 abnormality present vs. absent |
6 (3.0) |
3.65 |
1.42-9.44 |
0.007 |
NS |
NS |
NS |
| 19p13 abnormality present vs. absent |
16 (8.0) |
2.85 |
1.20-6.80 |
0.018 |
3.31 |
1.68-6.51 |
0.001 |
| 8q24 abnormality present vs. absent | 13 (6.5) | 2.54 | 1.24-5.23 | 0.011 | 2.43 | 1.24-4.73 | 0.009 |
*The multivariate Cox regression models initially included age, gender, the International Prognostic Index (IPI) risk groups, history of R-CHOP treatment, presence of histologic bone marrow involvement, and either presence of ≥ 2 cytogenetic abnormalities, or presence of specific cytogenetic abnormalities found in minimum 5 R-CHOP-treated patients and associated with significant poor prosnosis in the univariate analysis (+3, -17, abnormalities at 14q32, 3q25-q27, 19p13, 8q24, 7q22, 1q21-q23, 18q21, 19q13, 9q34, 22q11, 11q23-q25, 12q22-q24, 16q22-q24, and deletion 6q). The stepwise selection procedure was used to select variables in the final models.
Abbreviations: CI, confidence interval; HR, hazard ratio; NS, not significant.